Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Barrak, Dany; Villano, Anthony M.; Villafane-Ferriol, Nicole; Stockton, Leah G.; Hill, Maureen V.; Deng, Mengying; Handorf, Elizabeth A.; Reddy, Sanjay S.
• Is Part Of: European journal of surgical oncology. Volume 48:Issue 6(2022)
• Page Start: 1356
• Page End: 1361
• Publication Date: 2022-06
• Subjects: TNT -- Pancreas -- Chemoradiation -- Chemotherapy -- Radiation -- Whipple; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2021.12.473
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: Multiple neoadjuvant therapy protocols have been proposed in the treatment of pancreatic adenocarcinoma, including chemotherapy (CT), chemoradiation (CRT), and total neoadjuvant therapy (TNT), defined as a CT plus CRT. A pathologic complete response (pCR) can be achieved in a minority of cases. We hypothesize that TNT is more likely to confer pCR than other neoadjuvant therapies, which may improve overall survival (OS). Methods: A retrospective review of the National Cancer Database (NCDB) from 2006 to 2016 was performed, identifying patients who underwent any neoadjuvant therapy followed by definitive pancreatic resection for locally advanced or borderline resectable pancreatic adenocarcinoma. A pathologic complete response was defined as down-staging from any clinical stage to pathologic stage 0. Results: A total of 5402 patients who received neoadjuvant therapy followed by resection were identified. 177 patients (3.3%) achieved a pCR. Of the patients who achieved a pCR, 57 received CT, 41 CRT and 79 received TNT. On multivariate analysis, TNT was more likely to confer a pCR than CRT (OR 1.67, CI 1.13–2.46, p = 0.0103) or CT (OR 2.61, CI 1.83–3.71, p < 0.0001). Patients who achieved pCR had a significantly higher OS, with median survival of 64.9 months, compared to 21.6 months in patients who did not achieve pCR (p < 0.0001). Conclusion: TNT may be more likely to achieve a pCR than CT or CRT. Patients who achieve a pCR have a significant OS benefit as compared to those who have residual disease. TNT should be considered for patients requiring neoadjuvant therapy, as it may increase the likelihood of achieving a pCR, thus potentially improving OS.